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Sum m ary
In a randomised clinical trial, we compared the efficacy of the new triazole drug 
itraconazole (200 mg orally twice daily) with that of amphotericin B (o-6 mg/kg daily 
or 0*3 mg/kg in combination with flucytosine) in neutropenic (<  500x i 06/l 
neutrophils) patients with proven or highly suspected systemic fungal infections. 
Patients with unexplained fever alone were not included in the study. Of the 40 
patients enrolled, 32 patients (16 males, 16 females) were evaluable. Sixteen patients 
(median age 49 years) were treated with itraconazole for a median period of 20 days 
and 16 patients (median age 32 years) received amphotericin B for a median period of 
13 days. The overall clinical response was 10/16 (63%) for patients treated with 
itraconazole and 9/16 (56%) for patients treated with amphotericin B (P > 0-90). 
Itraconazole seemed to be more effective against Aspergillus infections, whereas 
amphotericin B seemed to be more effective against candidal infections, although the 
differences were not statistically significant.
Introduction
Systemic fungal infections continue to be a major threat to neutropenic 
patients, the most important causative agents being species of Candida and 
Aspergillus.1 The standard therapy for these infections is amphotericin B or a 
combination of amphotericin B and flucytosine in case of candidal infections.2 
Because the diagnosis of fungal infections is often established only at post­
mortem examination, many physicians administer empirical antifungal therapy 
to neutropenic patients with unexplained fever who do not respond to broad- 
spectrum antibacterial treatment.3,4 Treatment with these antifungal drugs, 
however, is often disappointing in neutropenic patients0 and may be associated 
with considerable side-effects. Therefore, more effective and less toxic 
antifungal drugs are needed. Itraconazole is a new triazole antifungal drug 
with activity against Candida and Aspergillus species both in vitro and in 
experimental animal infections.6-9 Deep-seated candidal infections and
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invasive aspergillosis have been treated effectively with itraconazole without 
apparent toxicity in non-neutropenic patients10,11 and, more recently, also in 
small numbers of neutropenic patients12,13 and in a patient with chronic 
granulomatous disease. 14 Because of its low degree of toxicity, the possibility 
of prolonged oral treatment with itraconazole could prove to be an important 
advantage over amphotericin B. Therefore, we conducted a prospective, 
randomised clinical trial in order to compare the efficacies of itraconazole and 
amphotericin B in neutropenic patients with proven or highly suspected 
systemic fungal infections.
M aterials and m ethods
Patients and definitions
Three hospitals, the Nijmegen University Hospital, the Leiden University 
Hospital and the Leyenburg Hospital of The Hague, took part in the study. 
All neutropenic patients with proven or suspected fungal infections were 
considered eligible for the study. Neutropenia was defined as fewer than 
500 x i o <5/1 neutrophils in the peripheral blood. The patients were nursed in 
protective isolation and received oral non-absorbable antimicrobial drugs, 
including amphotericin B, for selective decontamination of the gastro­
intestinal tract.15 Fungal infection was considered to be definite if fungi were 
cultured from deep tissues or sterile body fluids or were identified at these sites 
by cytological or histological examination. In the case of candidaemia, at least 
two blood cultures taken by venupuncture from different sites had to be 
positive with the same species. Because systemic fungal infections are often 
difficult to prove in neutropenic patients we also included patients with highly 
suspected fungal infection, i.e. those with a clinical site of infection without a 
known bacterial or viral causative agent. In the case of a pulmonary infiltrate 
without histological proof of deep tissue involvement, fungal infection was 
considered to be probable when Aspergillus species were isolated from the 
sputum and possible when Candida species were isolated. The distinction 
between Candida and Aspergillus was made because of the frequent isolation 
of Candida species from the skin and mucous membranes of neutropenic 
patients without signs of infection, whereas the isolation of Aspergillus species 
from the sputum of a neutropenic patient is considered to be highly indicative 
of the presence of this infection .18 Patients with unexplained fever as a single 
sign were excluded from the study. Patients unable to take oral medication 
were also excluded, as were patients who had to take H 2-receptor antagonists 
which may interfere with the absorption of itraconazole from the gastro­
intestinal tract.17
A patient was presumed to have responded to therapy when there was at 
least a 50% decrease in the size of the initial site or the severity of the infection 
or when all signs of infection had disappeared. If the fungal infection persisted 
or progressed, therapy was considered to have failed. If a patient had to 
discontinue treatment with itraconazole because of problems in swallowing 
oral medication, therapy was also considered a failure.
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Drug regim ens
Amphotericin B for intravenous use (Fungizone®, E. R. Squibb & Sons) and 
flucytosine (Ancotil®, Hoffmann LaRoche) were purchased from their 
respective manufacturers; itraconazole was provided by Janssen Pharma­
ceutics, Beerse, Belgium, in capsules containing 50 mg of the drug in 
polyethylene glycol. The study was approved by the ethical committees of the 
participating hospitals. After informed consent was obtained, each patient was 
randomised so as to receive either itraconazole or amphotericin B. The 
decision to combine amphotericin B with flucytosine for a candidal infection 
was made by the attending physician. After a test dose of 1 mg, the dose of 
amphotericin B was rapidly increased to o-6 m g/kg intravenously daily. When 
administered in combination with flucytosine (150 m g/kg daily), the dose of 
amphotericin B was lower (0-3 m g/kg). Itraconazole was administered orally 
at a dose of 200 mg every 12 h after a meal. When a patient was given 
itraconazole, oral amphotericin B for fungal prophylaxis was discontinued 
because of possible antagonism between azole drugs and amphotericin B .18
Laboratory evaluation
Blood counts, serum electrolytes, serum creatinine and liver enzymes were 
determined before antifungal treatment was started and twice weekly thereafter 
in order to monitor renal and hepatic toxicity and to assess bone marrow 
recovery. Renal toxicity was defined as an increase in serum creatinine of at 
least 30%, hepatic toxicity was defined as an increase in serum glutamic 
oxaloacetic transaminase (SG O T) or serum alkaline phosphatase of at least 
30% of the initial value obtained before treatment was started.
Statistical analysis
The x 2 test with the Yates-correction was used in order to compare the results 
of the two treatment groups.
Results
O f the 40 patients who entered the study, 32 were evaluable. Five patients 
should not have been included because of their not having any clinical site of 
infection. Three other patients were also excluded from further evaluation: 
one died only a few hours after therapy began and one proved to have bacterial 
pneumonia, while treatment with itraconazole had to be discontinued in 
another because of a rash.
Patient characteristics
O f the 32 evaluable patients, 16 were treated with itraconazole and 16 received 
amphotericin B; five of those treated with amphotericin B also received 
flucytosine. The patient characteristics were similar within the two treatment 
groups except for a higher median age for the patient treated with itraconazole 
(Table I). The most common underlying condition was acute leukaemia, 63 % 
all patients being severely neutropenic (<  100 x io 6/ l  neutrophils) at the time 
antifungal therapy began, either due to their disease or as a result of the 
cytostatic treatment.
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Table I Characteristics of 32 patients with suspected or proved fungal
infections
Characteristic
Patients treated with 
Amphotericin B* Itraconazole
Number of patients 16 16
Number of males 7 9
Number of females 9 7
Median age (years) 32 51
Age range (years) 19-51 15-74
Median duration of neutropenia before 11 10
treatment (days)
Number of patients with :
Leukaemia 14(8 8 % ) 1 3 ( 8 1 % )
Lymphoma 1 ( 6 % ) 2 (13 % )
Othersf 1 ( 6 % ) 1 ( 6 % )
Number of patients with h  (69% ) 9 (5 6 % )
neutrophils < 100 x io 6/l
* Five patients received amphotericin B combined with flucytosine.
f  One patient with aplastic anaemia treated with amphotericin B and one patient with 
multiple myeloma treated with itraconazole.
Fungal infections
Fungal infection was definite in seven, probable in 11 and possible in 14 cases. 
The causative agent was Candida in 16 cases (Candida albicans: 15 patients; 
Candida sp .: one patient) and Aspergillus in 13 cases {Aspergillus fumigatus: 
seven patients; A. nig er: one patient; A. flavus: one patient; Aspergillus sp p .: 
four patients). In three patients with possible fungal infection, a causative agent 
could not be identified. The most common site of infection was the lung, 
pulmonary infiltrates being present in 27 of the 32 patients. One patient 
treated with itraconazole had both pulmonary and paranasal aspergillosis, 
whereas one patient receiving amphotericin B had combined pulmonary and 
cerebral aspergillosis. In addition, two patients treated with itraconazole had 
candidaemia, whereas two patients receiving amphotericin B had oesophagitis 
and one had endophthalmitis.
Clinical efficacy
The median duration of treatment was 20 days (range 1-10 4  days) for patients 
treated with itraconazole and 13 days (range 7 -5 7  days) for those receiving 
amphotericin B. The median cumulative dose of amphotericin B administered 
was 318 mg (range 166-1560  mg). Concomitant antibiotic therapy was 
administered to 13 patients on itraconazole and 11 patients on amphotericin B. 
The overall response to treatment is shown in Table II. Ten of 16 patients 
(6 3 %) treated with itraconazole and nine of 16 patients (5 6 %) receiving 
amphotericin B responded to treatment (P >  0-90). Three patients received 
itraconazole for less than 3 days because of an inability to swallow oral
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Table II Clinical outcome of 32 patients with suspected or proved fungal
infections
Patients treated with
Amphotericin B* Itraconazole
Fungal
infection
Number of 
patients
Number
responding
Number of 
patients
Number
responding
Candidiasis
Definite I 0 3 0
Probable I I ----------
Possible 8 6 3 2
Aspergillosis
Definite 2 0 I I
Probable 3 2 7 5
Unknown I 0 2 2
Total 16 9 16 10
* Five patients received amphotericin B combined with flucytosine.
medication. When these patients are excluded, the overall response to 
treatment with itraconazole was 7 7 %. When definite and probable infections 
are taken together, six of n  patients treated with itraconazole and three of 
seven patients receiving amphotericin B responded to treatment (P > 0*90). 
Tw o of six patients with Candida infections treated with itraconazole and 
seven of 10 patients receiving amphotericin B responded to treatment. Six of 
eight patients with Aspergillus infections treated with itraconazole and two of 
five patients receiving amphotericin B responded also.
Overall, 13 of 15 patients with neutrophil recovery (>  500 x io 6/l)  during 
treatment and only six of 17 patients without neutrophil recovery responded 
to treatment (P <  o-oi). Although this trend was apparent for patients 
receiving itraconazole as well as amphotericin B, the numbers within the 
treatment groups were too small to reach statistical significance.
Four patients treated with itraconazole and six having amphotericin B died 
during the period of treatment or shortly ( <  3 days) thereafter ; autopsy 
findings were available for seven of these patients. For patients receiving 
itraconazole, the causes of death were cerebral haemorrhage (one patient), 
interstitial pneumonitis (one patient), polymicrobial septicaemia (including 
candidaemia) (one patient) and pulmonary candidiasis (one patient). For 
patients treated with amphotericin B the causes of death were Pseudomonas 
septicaemia (one patient), interstitial pneumonitis (two patients) and invasive 
aspergillosis (three patients).
Itraconazole p lasm a concentrations
Blood samples were drawn from eight patients 3 h after oral administration of 
200 mg itraconazole for determination of the plasma concentration by high- 
pressure liquid chromatography (Janssen Pharmaceutics, Beerse, Belgium).
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Table III Renal and hepatic toxicity
Findings in 20 patients with abnormal*
values during treatment with
Laboratory Amphotericin B f Itraconazole
test (20 patients) (20 patients)
Serum creatinine 6 (30%) 3 (15 % )
Serum alkaline phosphatase 5 (25 % ) 2 ( 1 0 % )
S G O T 11 (5 5 % ) 8 (4 0 % )
* > 3 0 %  increase in pretreatment values.
f  Five patients received amphotericin B combined with flucytosine. 
S G O T  = serum oxaloacetic transamiase.
The plasma concentration varied between 192 and 2045 ng/m l for five patients 
who responded to treatment and between 16 and 666 ng/m l for three patients 
who did not respond to treatment.
Side effects
Fever and chills were seen in five of 20 patients treated with amphotericin B 
despite premedication with pethidine. In one case, treatment with itraconazole 
had to be discontinued because of the appearance of a generalised rash shortly 
after administration of the drug on two consecutive occasions. Laboratory 
evaluation revealed renal toxicity in six of 20 patients treated with 
amphotericin B and three of 20 patients treated with itraconazole (P  =  0-4 5 ; 
Table III). Renal toxicity contributed to the death of one patient on 
amphotericin B and necessitated discontinuation of the drug in another. 
Nephrotoxicity was reversible in two patients receiving itraconazole despite 
continuation of the drug and was probably related to shock in a third case. 
There was no difference in the incidence of hepatoxicity (Table III).
Discussion
In the present study, we found no significant difference between the efficacies 
of itraconazole and amphotericin B against systemic fungal infections in 
neutropenic patients. Even so, we recognise the fact that the number of 
patients in the study was too small so as to fully exclude superiority of one of 
the two drugs.
A large proportion (41 %) of the fungal infections was caused by Aspergillus 
spp., whereas in most studies over 80% of the fungal infections are caused by 
species of Candida.19 The explanation for this difference may be two-fold. 
First, in order to be able to discriminate between infection and colonisation, 
the criteria for candidal infections were stricter than those for Aspergillus 
infections. Secondly, the relative frequency of Aspergillus infections compared 
to candidal infections may have been enhanced by the use of non-absorbable 
antimicrobial drugs, including oral and local amphotericin B, for preventing 
infection in our patients.10 This regimen, in combination with the restricted
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use of broad-spectrum antibiotics, has proved to be effective in the prevention 
of Gram-negative and candidal infections but is less effective as prophylaxis 
against Aspergillus infections. Despite the grave prognosis for Aspergillus 
infections in neutropenic patients, the efficacy of itraconazole against these 
infections was favourable in our study since six of eight patients responded to 
treatment. None of the patients given itraconazole died of aspergillosis, 
whereas three patients treated with amphotericin B died of invasive 
aspergillosis. Itraconazole seemed somewhat less effective than amphotericin 
B against candidal infections, although the difference was not statistically 
significant. Moreover, two patients who failed to respond to itraconazole, but 
none of the patients treated with amphotericin B, had candidaemia.
The daily dose of amphotericin B used in our study (maximal o-6 m g/kg) was 
lower than that recommended by some authors and the duration of treatment 
was rather short. Even so, there is no general agreement on the daily dose of 
amphotericin B that should be administered to neutropenic patients with 
systemic fungal infections and the doses used in this study agree with the 
recommendations made.20 The median duration of treatment of fungal 
infections in neutropenic patients is determined by the complicated course in 
this group of patients and was comparable to the duration of treatment 
reported.19
At the time of this study, the most important limitation on the use of 
itraconazole was the absence of an intravenous form of the drug and the 
variable absorption after oral administration in patients with gastro-intestinal 
disturbances. Indeed, plasma concentrations of itraconazole tended to be 
lower in patients who did not respond to treatment compared to patients who 
did respond to treatment. Plasma concentrations were not obtained for three 
other patients who had to discontinue treatment with itraconazole within 3 
days because of difficulties in swallowing the drug; presumably, their plasma 
concentrations were very low. Although the antifungal efficacy of itraconazole 
is difficult to evaluate in these patients, we included them as failures in the 
evaluation of the response to treatment because we wanted to compare the 
usefulness of the two drugs in the situation in which systemic fungal infections 
arise.
Only very recently has an intravenous form of itraconazole been developed. 
It is now being evaluated for safety in volunteers (G. Cauwenbergh, personal 
communication). All being well, this new form of itraconazole should result in 
a major improvement in the application of the drug in patients with inadequate 
absorption.
Although our study was designed as a conventional clinical trial of efficacy, 
a more appropriate approach may be to try to establish equivalence between 
the two treatments.21 If this were to be the case, itraconazole should be 
preferred to amphotericin B because it is less toxic and because of the 
possibility of prolonged oral treatment for outpatients.
In conclusion, the present study indicates that itraconazole may be a useful 
new drug against systemic fungal infections in neutropenic patients. Larger 
studies, preferably with an intravenous form of itraconazole, are necessary in 
order, hopefully, to establish more firmly the efficacy of itraconazole compared 
to that of amphotericin B.
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